Global Intelligence Database
With a 90 per cent failure rate for brain cancer drugs in late-stage trials, researchers are moving away from animal testing. A new approach proposes 'preclinical trials' using living patient tissue to better predict how treatments will work in humans.
By Adefolaju, Kram, Mann, Hingtgen, Satterlee
Exome sequencing (ES) transforms diagnostics by focusing strictly on protein-coding regions, where many disease-causing mutations hide. This review details how ES powers personalised medicine—from rare disease identification to pharmacogenomics—while addressing the ethical and technical challenges involved.
By Manjunath, Verma, Berua, Mahalingam, Dakal, Kumar
A new roadmap argues that generic safety models are becoming insufficient for modern medicine. It calls for a shift toward personalized assessments across the electromagnetic spectrum to ensure safe, effective treatment for individual patients.
By Laakso, Paulides, Kodera, Ahn, Brace, Cavagnaro, Chen, Deng, De Santis, Diao, Farrugia, Feliziani, Fiocchi, Fioranelli, Hikage, Makaroff, Mizuno, Opitz, Pickwell-MacPherson, Prakash, Rodrigues, Sasaki, Sakamoto, Taylor, Visser, Yeo, Hirata